Rhythm Pharmaceuticals Announces Public Reimbursement for IMCIVREE® (setmelanotide) in Canada in Five Provinces and Under the Federal Non-Insured Health Benefits Program

Core Insights - Rhythm Pharmaceuticals has entered into Product Listing Agreements for IMCIVREE in several Canadian provinces, allowing public reimbursement for eligible patients with Bardet-Biedl syndrome and obesity [1][2][3] - The approval of IMCIVREE by Health Canada in May 2023 and its inclusion in the National Strategy for Drugs for Rare Diseases is a significant advancement for patients [2][4] - The agreements highlight the recognition of the burden of obesity associated with Bardet-Biedl syndrome and the company's commitment to equitable access for all patients in Canada [3][4] Company Overview - Rhythm Pharmaceuticals is a biopharmaceutical company focused on rare neuroendocrine diseases, with its lead product IMCIVREE (setmelanotide) approved for weight management in patients with specific genetic conditions [4][5] - IMCIVREE is indicated for weight management in patients aged 6 years and older with obesity due to Bardet-Biedl syndrome and other genetic deficiencies [5][6] - The company is also advancing a clinical development program for additional rare diseases and investigational MC4R agonists [4][5] Product Information - IMCIVREE is an MC4R agonist that has received regulatory approvals in Canada, the U.S., and Europe for treating obesity related to Bardet-Biedl syndrome and other genetic conditions [4][6][8] - The product is administered via subcutaneous injection and is indicated for patients with genetically confirmed conditions [5][6] - The company emphasizes the importance of physician supervision for prescribing IMCIVREE in the EU and UK [8]